Oncology – Head and Neck
RCT | Upfront radiosurgery reduces tumor volume vs. a wait-and-scan approach in small- to medium-sized vestibular schwannoma
7 Aug, 2023 | 14:40h | UTCUpfront Radiosurgery vs a Wait-and-Scan Approach for Small- or Medium-Sized Vestibular Schwannoma: The V-REX Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
Commentary on Twitter
Among patients with small or medium vestibular schwannoma, a treatment strategy consisting of upfront radiosurgery was more effective at reducing tumor volume at 4 years than was the initial wait-and-scan approach. https://t.co/Qv3YZVsq2Q pic.twitter.com/aNeu7MJfl0
— JAMA (@JAMA_current) August 2, 2023
Review | The evolving landscape of salivary gland tumors
27 Jul, 2023 | 12:58h | UTCThe evolving landscape of salivary gland tumors – CA: A Cancer Journal for Clinicians
RCT | Dysphagia-optimized intensity-modulated radiotherapy better preserves swallowing function in pharyngeal cancer patients
25 Jul, 2023 | 13:52h | UTCCommentaries:
Radiation approach improves swallowing in head, neck cancer – MDedge
Commentary on Twitter
NOW OF: The (DARS) phase 3 RCT investigates if dysphagia-optimised intensity-modulated radiotherapy (IMRT) reduces radiation dose to the dysphagia and aspiration related structures and improves swallowing function compared with standard IMRT.#hncsmhttps://t.co/CzpxsNxx1N pic.twitter.com/xNgfm43tHE
— The Lancet Oncology (@TheLancetOncol) July 7, 2023
TTMV-HPV DNA testing | Promising diagnostic and surveillance tool for HPV-linked oropharyngeal cancer
17 Jul, 2023 | 13:25h | UTCPerformance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus–Associated Oropharyngeal Cancer – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)
Invited Commentary: Circulating Human Papillomavirus Tumor DNA—Ready for Prime Time? – – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)
2023 ETA clinical practice guidelines for thyroid nodule management
12 Jul, 2023 | 13:48h | UTC
The 2023 Bethesda System for reporting thyroid cytopathology
12 Jul, 2023 | 13:46h | UTCThe 2023 Bethesda System for Reporting Thyroid Cytopathology – Thyroid
RCT | Cisplatin–gemcitabine improves 3-year progression-free survival in N2–3 nasopharyngeal carcinoma compared to cisplatin–fluorouracil
16 Jun, 2023 | 14:05h | UTCConcurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NOW OF: Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialhttps://t.co/n6WalQiRfo pic.twitter.com/vE4VASUIgM
— The Lancet Oncology (@TheLancetOncol) June 5, 2023
Review | Updated salivary gland immunohistochemistry
5 May, 2023 | 14:55h | UTCUpdated Salivary Gland Immunohistochemistry: A Review – Archives of Pathology & Laboratory Medicine
RCT | Effects of Docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation
29 Mar, 2023 | 13:05h | UTCResults of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation – Journal of Clinical Oncology (link to abstract – $ for full-text)
Editorial: Good Radiosensitizer Hunting – Journal of Clinical Oncology
Commentaries:
Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC – OncLive
RCT | Hyperfractionation vs. standard fractionation in IMRT for patients with locally advanced recurrent nasopharyngeal carcinoma
22 Mar, 2023 | 13:12h | UTCHyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Feasibility and efficacy of microwave ablation in the treatment of papillary thyroid microcarcinoma: a prospective cohort study
14 Mar, 2023 | 13:30h | UTCMicrowave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study – Radiology (link to abstract – $ for full-text)
RCT | Medial retropharyngeal nodal region sparing radiotherapy vs. standard radiotherapy in patients with nasopharyngeal carcinoma
7 Feb, 2023 | 14:09h | UTC
Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
27 Jan, 2023 | 12:16h | UTC
RCT | Nivolumab plus Ipilimumab vs. EXTREME regimen as first-line treatment for recurrent/metastatic head and neck cancer
19 Jan, 2023 | 13:41h | UTC
NICE Guideline | Thyroid cancer: assessment and management
11 Jan, 2023 | 14:34h | UTCThyroid cancer: assessment and management – National Institute for Health and Care Excellence
ASCO Guideline | Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers
9 Jan, 2023 | 14:41h | UTCNews Release: ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer – ASCO Daily News
Cohort Study | Lobectomy vs. total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis.
6 Dec, 2022 | 13:41h | UTCComparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis – JAMA Surgery (free for a limited period)
Invited Commentary: Is Lobectomy as Effective as Total Thyroidectomy in Treating Patients With Intermediate-Risk Papillary Thyroid Carcinoma With Lateral Lymph Node Metastasis? – JAMA Surgery (free for a limited period)
Commentary on Twitter
Study of patients with papillary thyroid carcinoma and lymph node metastases found that recurrence-free survival was similar after lobectomy and total #thyroidectomy. https://t.co/07mMcczp1T
— JAMA Surgery (@JAMASurgery) December 1, 2022
Case–control study | GLP-1 receptor agonists linked to increased risk of thyroid cancer.
25 Nov, 2022 | 12:42h | UTCGLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Diabetes Care (link to abstract – $ for full-text)
Commentary: GLP-1 receptor agonists associated with thyroid cancer – ACP Internist
RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.
7 Nov, 2022 | 12:26h | UTCLow-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
Low-Dose Immunotherapy has made immunotherapy more accessible, and has brought down the cost of therapy from 60-80 lakhs to below 5.0 lakhs per year. Hugh cost saving. A step towards atmanirbhar Bharat. @PMOIndia @TOIIndiaNews @ndtv @ZeeNews @the_hindu https://t.co/c0WuC9Wlfk
— Dr. Vijay Patil (@DrVijayPatil11) October 21, 2022
2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.
27 Oct, 2022 | 12:33h | UTCCommentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)
RCT | Adjuvant capecitabine following concurrent CTX-RT in locoregionally advanced nasopharyngeal carcinoma.
17 Oct, 2022 | 12:15h | UTC
4-year follow-up of a RCT | Pembrolizumab with vs. without chemotherapy in recurrent or metastatic head and neck SCC.
14 Oct, 2022 | 14:11h | UTCOriginal Study: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Guideline Summary | Recommendations for care of survivors of head and neck cancer.
7 Oct, 2022 | 14:15h | UTCRecommendations for Care of Survivors of Head and Neck Cancer – JAMA (free for a limited period)
Original Guideline: Head and neck cancer survivorship consensus statement from the American Head and Neck Society – Laryngoscope Investigative Otolaryngology
Related:
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
RCT | Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer.
3 Oct, 2022 | 13:42h | UTCCommentary: Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer – Cancer Therapy Adviser
Commentary on Twitter
❎ ASTRA trial: Radioactive iodine ± selumetinib doesn't improve remission rates for high-risk #thyroidcancer
✅ Postoperative pathologic risk stratification identified pts at risk of primary treatment failurehttps://t.co/kvakaMXtDh#JCO #thycsm @MSKCancerCenter pic.twitter.com/mvQwgzIjWh— Journal of Clinical Oncology (@JCO_ASCO) March 16, 2022
M-A of randomized trials | Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence.
21 Sep, 2022 | 13:07h | UTCProphylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence: A Meta-analysis of Randomized Trials – Annals of Surgery (link to abstract – $ for full-text)